CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Complement dosageWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug241 Cytokines dosage Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018746 Systemic Inflammatory Response Syndrome NIH 0.58

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome

In patients infected by the SARS-Cov-2 Coronavirus a severely progressive disease requiring hospitalization in intensive care seems related to deregulation of cytokines with very high levels of IL-6, IL-2, IL-7, IL-10 and TNF-α. In order to elucidate the mechanism of this hyper inflammatory syndrome we will measure a panel of pro and anti inflammatory cytokines, as well as known markers of macrophage activation syndrome. To determine the role of activation of the complement cascade the most important complement factors and their activation markers will be measured. The changes of those parameters will be monitored after administration of an anti-IL6R antibody therapy.

NCT04346017 COVID-19 Diagnostic Test: Cytokines dosage Diagnostic Test: Complement dosage
MeSH:Systemic Inflammatory Response Syndrome

Primary Outcomes

Description: Interleukine 6, soluble IL6-R, complex IL6-IL6R concentration

Measure: IL6 concentration

Time: Before anti-IL6R treatment (baseline)

Description: Interleukine 6 soluble IL6-R, complex IL6-IL6R variation compared to baseline value

Measure: IL6 concentration change from baseline value

Time: Twice a week from day 1 to day 14 post anti-IL6R administration

Description: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2

Measure: Complement parameters

Time: Before anti-IL6R treatment (baseline)

Description: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2 variation compared to baseline values

Measure: Complement parameters change from baseline values

Time: Twice a week from day 1 to day 14 post anti-IL6R administration

Description: Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18

Measure: Inflammatory cytokines baseline concentrations

Time: Before anti-IL6R treatment (baseline)

Description: Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18 variation compared to baseline values

Measure: Inflammatory cytokines change from baseline values

Time: Twice a week from day 1 to day 14 post anti-IL6R administration

Secondary Outcomes

Description: sCD25, sCD163, sCD14, glycosylated ferritin

Measure: Concentration of markers of macrophage activation

Time: Before anti-IL6R treatment (baseline)

Description: sCD25, sCD163, sCD14, glycosylated ferritin variation compared to baseline values

Measure: Markers of macrophage activation change from baseline values

Time: Twice a week from day 1 to day 14 post anti-IL6R administration

No related HPO nodes (Using clinical trials)